The Company’s AntiSense molecular diagnostic platform is being developed for use at Point of Care (POC) to test on-site, and In Home (HUT) for a wide range of viral and other diseases.
The Company’s first products are AntiSense molecular diagnostic test kits that accurately, quickly and affordably detect respiratory infections, including Covid-19 in less than 5 minutes.
Deployed at the point of entry of high traffic venues such as airports, shopping malls, office buildings, sporting venues, manufacturing plants, hospitals, pharmacies, nursing and long-term care homes the AntiSense POC molecular diagnostic test kit will contribute to safe reopening of the economy. The AnitSense HUT molecular diagnostic test kit will further allow for quick, easy, and accurate in home self-testing, allowing the economy to remain open.
Insert patient sample swab into cartridge, close cap of cartridge, insert cartridge into instrument reader to individually run diagnostic test. Once test cycle completes the result will automatically be sent to electronic devices - smart phones, Ipads or computers.
We have established a world class executive leadership team, Board of Directors and Board of Advisors, with experience in healthcare, life sciences, medical devices, diagnostics, biotechnology, nanomedicine, drug delivery, and pharmaceuticals. Our financial advisors have decades of global experience in investment banking in the private and public sector.LEARN MORE
RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care (“POC”) and home-use infectious disease detection, announced today the appointments of its Chief Scientific Advisor, Professor Dipanjan Pan, M.S., Ph.D., and its President, John W. Erickson, Jr., to the Company’s Board of Directors.Read More
RNA Disease Diagnostics, Inc. (“RNADD” or the “Company”), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today that it has secured an exclusive global license to a rapid ribonucleic acid (“RNA”)-based molecular Lateral Flow Assay (“LFA”) technology jointly owned by the University of Maryland, Baltimore (“UMB”) and the University of Maryland, Baltimore County (“UMBC”).Read More